Expertise in
18
conditions

Dr. Anthony R. Mato

Hematology
Cayuga Medical Center At Ithaca
101 Dates Dr, 
Ithaca, NY 
Offers Telehealth
Expertise in
18
conditions
Cayuga Medical Center At Ithaca
101 Dates Dr, 
Ithaca, NY 

Overview

Anthony Mato is a Hematologist practicing medicine in Ithaca, New York.

Dr. Mato is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 177 peer reviewed articles and participating in 10 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NY

Hospital Affiliations

Arnot Ogden Medical Center
Ira Davenport Memorial Hospital
Schuyler Hospital
Cayuga Medical Center At Ithaca

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Cayuga Medical Center at Ithaca
101 Dates Dr, Ithaca, NY 14850
Other Locations
Memorial Hospital for Cancer & Allied Diseases
136 Mountainview Blvd, Basking Ridge, NJ 07920

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients
Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drugs: Venetoclax, Venetoclax+anti CD20 monoclonal antibody
Study Phase: Phase 2
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
Enrollment Status: Active_not_recruiting
Publish Date: July 07, 2026
Intervention Type: Drug
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 2
A Phase 2 Time Limited Approach Based on Depth of Response to Front-Line Acalabrutinib in Combination With Obinutuzumab for CLL/SLL Patients Who Achieve Complete Remission or Partial Remission With Undetectable Minimal Residual Disease
A Phase 2 Time Limited Approach Based on Depth of Response to Front-Line Acalabrutinib in Combination With Obinutuzumab for CLL/SLL Patients Who Achieve Complete Remission or Partial Remission With Undetectable Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drugs: Acalabrutinib, Obinutuzumab
Study Phase: Phase 2
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance
Enrollment Status: Completed
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drugs: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: January 27, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 1
Clonal Evolution of B Cells in High-risk Chronic Lymphocytic Leukemia Patients After Idelalisib-rituximab Treatment
Clonal Evolution of B Cells in High-risk Chronic Lymphocytic Leukemia Patients After Idelalisib-rituximab Treatment
Enrollment Status: Withdrawn
Publish Date: April 16, 2019
Intervention Type: Other
View 8 Less Clinical Trials

177 Total Publications

Excess folate elevates formaldehyde genotoxicity in cell lines but not in mice or humans.
Excess folate elevates formaldehyde genotoxicity in cell lines but not in mice or humans.
Journal: EMBO molecular medicine
Published: March 23, 2026
Similar Doctors
Expertise in
49
conditions
Expertise in
49
conditions
Referral may be required

Cayuga Cancer Center At Cortland

1081 Commons Ave, 
Cortland, NY 
 (19.4 miles away)
607-272-5414
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Bael is a Hematologist practicing medicine in Cortland, New York. Dr. Bael is highly rated in 49 conditions, according to our data. His clinical expertise encompasses Primary Lymphoma of the Brain, Large-Cell Immunoblastic Lymphoma, Waldenstrom Macroglobulinemia, Bone Marrow Aspiration, and Endoscopy.

Expertise in
22
conditions
Dr. Robert W. Horowitz
Hematology | Oncology
Expertise in
22
conditions
Dr. Robert W. Horowitz
Hematology | Oncology
Referral may be required

Cayuga Medical Center At Ithaca

101 Dates Dr, 
Ithaca, NY 
 (0.1 miles away)
607-272-5414
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Horowitz is a Hematologist and an Oncologist practicing medicine in Ithaca, New York. Dr. Horowitz is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Small Lymphocytic Lymphoma (SLL), Leukocytosis, Breast Cancer, and Bone Marrow Aspiration.

Expertise in
16
conditions
Dr. Paul C. Coty
Hematology | Oncology
Expertise in
16
conditions
Dr. Paul C. Coty
Hematology | Oncology
Referral may be required

The Renzi Cancer Center At Guthrie Cortland Medical Center

34 W Main St, 
Cortland, NY 
 (18.5 miles away)
607-756-3130
Languages Spoken:
English
See accepted insurances

Paul Coty is a Hematologist and an Oncologist practicing medicine in Cortland, New York. Dr. Coty is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Junction Cancer, Familial Colorectal Cancer, Chronic Lymphocytic Leukemia (CLL), and Colorectal Cancer.

Frequently Asked Questions about Dr. Anthony R. Mato

How do I make an appointment with Dr. Anthony R. Mato?

You can book an appointment with Dr. Anthony R. Mato by calling their office at 607-272-5414. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anthony R. Mato a top-rated expert for Chronic B-Cell Leukemia (CBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anthony R. Mato is classified as an Elite expert for Chronic B-Cell Leukemia (CBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anthony R. Mato specialize in?

While Dr. Anthony R. Mato is a Hematology, they have specific expertise in Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Anthony R. Mato participate in research or clinical trials?

Yes. Dr. Anthony R. Mato has published 177 articles and abstracts on conditions like Chronic B-Cell Leukemia (CBCL). You can view a list of Dr. Anthony R. Mato's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anthony R. Mato accept my insurance?

Dr. Anthony R. Mato accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 607-272-5414 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mato's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile